GIA632 clinical trials
GIA632 is named as an intervention in 3 current clinical trials in our USA, Canada, China, Australia, Germany, France, Poland, Czechia, Singapore, India, Spain, Italy, Netherlands and Japan registers. 2 are recruiting patients now. All registered phases are Phase 2. The lead sponsor is Novartis Pharmaceuticals. The most-studied condition is Cutaneous Lichen Planus. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Patient leaflets for GIA632
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of GIA632
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177 · Non-segmental Vitiligo
|
Phase 2 | Recruiting | Novartis Pharmaceuticals | USA, India, China, Germany, France, Spain, Italy, Netherlands, Canada, Japan, Australia |
|
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
NCT07775924 · ClinicalTrials.gov ↗ · Cutaneous Lichen Planus
|
Phase 2 | Recruiting | Novartis Pharmaceuticals | USA, China, Canada, Australia |
|
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT07220577 · Atopic Dermatitis
|
Phase 2 | Active, closed | Novartis Pharmaceuticals | USA, Germany, France, Poland, Czechia, Canada, Singapore |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
GIA632 in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing GIA632. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase IIb multicenter, randomized, double-blind, placebo-controlled, dose-range study to assess the efficacy and safety of GIA632 in participants with moderate to severe cutaneous lichen planus, followed by an extension period
2025-522300-25-00 · CTIS ↗ · Immune System Diseases
|
Phase 2 | Authorised | Novartis Pharma AG | Italy, Netherlands, Poland + 3 more |
Conditions studied with GIA632
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 3 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Questions about GIA632 trials
How many clinical trials are testing GIA632?
3 current trials in our USA, Canada, China, Australia, Germany, France, Poland, Czechia, Singapore, India, Spain, Italy, Netherlands and Japan registers name GIA632 as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are GIA632 trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 2 with sites in USA, 2 with sites in Canada, 2 with sites in China, 2 with sites in Australia, 1 with sites in Germany, 1 with sites in France, 1 with sites in India, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Netherlands and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors GIA632 clinical trials?
The lead sponsor is Novartis Pharmaceuticals. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how GIA632 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how GIA632 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists GIA632 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.